454 related articles for article (PubMed ID: 10713166)
21. Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization.
Gregory MA; Qi Y; Hann SR
J Biol Chem; 2003 Dec; 278(51):51606-12. PubMed ID: 14563837
[TBL] [Abstract][Full Text] [Related]
22. Ubiquitination is required for the retro-translocation of a short-lived luminal endoplasmic reticulum glycoprotein to the cytosol for degradation by the proteasome.
de Virgilio M; Weninger H; Ivessa NE
J Biol Chem; 1998 Apr; 273(16):9734-43. PubMed ID: 9545309
[TBL] [Abstract][Full Text] [Related]
23. Detection of genomic aberrations in molecularly defined Burkitt's lymphoma by array-based, high resolution, single nucleotide polymorphism analysis.
Scholtysik R; Kreuz M; Klapper W; Burkhardt B; Feller AC; Hummel M; Loeffler M; Rosolowski M; Schwaenen C; Spang R; Stein H; Thorns C; Trümper L; Vater I; Wessendorf S; Zenz T; Siebert R; Küppers R;
Haematologica; 2010 Dec; 95(12):2047-55. PubMed ID: 20823134
[TBL] [Abstract][Full Text] [Related]
24. Identification of a C-terminal tripeptide motif involved in the control of rapid proteasomal degradation of c-Fos proto-oncoprotein during the G(0)-to-S phase transition.
Acquaviva C; Brockly F; Ferrara P; Bossis G; Salvat C; Jariel-Encontre I; Piechaczyk M
Oncogene; 2001 Nov; 20(51):7563-72. PubMed ID: 11709728
[TBL] [Abstract][Full Text] [Related]
25. B-Myc is preferentially expressed in hormonally-controlled tissues and inhibits cellular proliferation.
Gregory MA; Xiao Q; Cornwall GA; Lutterbach B; Hann SR
Oncogene; 2000 Oct; 19(42):4886-95. PubMed ID: 11039906
[TBL] [Abstract][Full Text] [Related]
26. Tuberous sclerosis complex is required for tumor maintenance in MYC-driven Burkitt's lymphoma.
Hartleben G; Müller C; Krämer A; Schimmel H; Zidek LM; Dornblut C; Winkler R; Eichwald S; Kortman G; Kosan C; Kluiver J; Petersen I; van den Berg A; Wang ZQ; Calkhoven CF
EMBO J; 2018 Nov; 37(21):. PubMed ID: 30237309
[TBL] [Abstract][Full Text] [Related]
27. beta-catenin is a target for the ubiquitin-proteasome pathway.
Aberle H; Bauer A; Stappert J; Kispert A; Kemler R
EMBO J; 1997 Jul; 16(13):3797-804. PubMed ID: 9233789
[TBL] [Abstract][Full Text] [Related]
28. The degradation of nascent fibrinogen chains is mediated by the ubiquitin proteasome pathway.
Xia H; Redman C
Biochem Biophys Res Commun; 1999 Aug; 261(3):590-7. PubMed ID: 10441471
[TBL] [Abstract][Full Text] [Related]
29. The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription.
von der Lehr N; Johansson S; Wu S; Bahram F; Castell A; Cetinkaya C; Hydbring P; Weidung I; Nakayama K; Nakayama KI; Söderberg O; Kerppola TK; Larsson LG
Mol Cell; 2003 May; 11(5):1189-200. PubMed ID: 12769844
[TBL] [Abstract][Full Text] [Related]
30. Regulation of the level of Vesl-1S/Homer-1a proteins by ubiquitin-proteasome proteolytic systems.
Ageta H; Kato A; Hatakeyama S; Nakayama K; Isojima Y; Sugiyama H
J Biol Chem; 2001 May; 276(19):15893-7. PubMed ID: 11278836
[TBL] [Abstract][Full Text] [Related]
31. The block to transcription elongation is promoter dependent in normal and Burkitt's lymphoma c-myc alleles.
Spencer CA; LeStrange RC; Novak U; Hayward WS; Groudine M
Genes Dev; 1990 Jan; 4(1):75-88. PubMed ID: 2307371
[TBL] [Abstract][Full Text] [Related]
32. Ongoing mutations in the N-terminal domain of c-Myc affect transactivation in Burkitt's lymphoma cell lines.
Albert T; Urlbauer B; Kohlhuber F; Hammersen B; Eick D
Oncogene; 1994 Mar; 9(3):759-63. PubMed ID: 8108117
[TBL] [Abstract][Full Text] [Related]
33. Oxidized LDLs alter the activity of the ubiquitin-proteasome pathway: potential role in oxidized LDL-induced apoptosis.
Vieira O; Escargueil-Blanc I; Jürgens G; Borner C; Almeida L; Salvayre R; Nègre-Salvayre A
FASEB J; 2000 Mar; 14(3):532-42. PubMed ID: 10698969
[TBL] [Abstract][Full Text] [Related]
34. Ubiquitination and proteasome mediated degradation of polo-like kinase.
Ferris DK; Maloid SC; Li CC
Biochem Biophys Res Commun; 1998 Nov; 252(2):340-4. PubMed ID: 9826531
[TBL] [Abstract][Full Text] [Related]
35. In vivo ubiquitination and proteasome-mediated degradation of p53(1).
Maki CG; Huibregtse JM; Howley PM
Cancer Res; 1996 Jun; 56(11):2649-54. PubMed ID: 8653711
[TBL] [Abstract][Full Text] [Related]
36. Regulatory elements in the immunoglobulin kappa locus induce c-myc activation and the promoter shift in Burkitt's lymphoma cells.
Polack A; Feederle R; Klobeck G; Hörtnagel K
EMBO J; 1993 Oct; 12(10):3913-20. PubMed ID: 8404859
[TBL] [Abstract][Full Text] [Related]
37. CD4 glycoprotein degradation induced by human immunodeficiency virus type 1 Vpu protein requires the function of proteasomes and the ubiquitin-conjugating pathway.
Schubert U; Antón LC; Bacík I; Cox JH; Bour S; Bennink JR; Orlowski M; Strebel K; Yewdell JW
J Virol; 1998 Mar; 72(3):2280-8. PubMed ID: 9499087
[TBL] [Abstract][Full Text] [Related]
38. Bryostatin 1 induces ubiquitination and proteasome degradation of Bcl-2 in the human acute lymphoblastic leukemia cell line, Reh.
Wall NR; Mohammad RM; Reddy KB; Al-Katib AM
Int J Mol Med; 2000 Feb; 5(2):165-71. PubMed ID: 10639596
[TBL] [Abstract][Full Text] [Related]
39. Adhesion-regulated G1 cell cycle arrest in epithelial cells requires the downregulation of c-Myc.
Benaud CM; Dickson RB
Oncogene; 2001 Jul; 20(33):4554-67. PubMed ID: 11494151
[TBL] [Abstract][Full Text] [Related]
40. The intron enhancer of the immunoglobulin kappa gene activates c-myc but does not induce the Burkitt-specific promoter shift.
Polack A; Strobl L; Feederle R; Schweizer M; Koch E; Eick D; Wiegand H; Bornkamm GW
Oncogene; 1991 Nov; 6(11):2033-40. PubMed ID: 1945409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
